MRS2690
MRS2690 is a selective P2Y14 receptor agonist. MRS2690 inhibits adenylyl cyclase activity, thereby reducing intracellular cAMP levels and mediating concentration-dependent vasoconstriction of porcine coronary arteries. MRS2690 induces intracellular calcium mobilization, activates P38 and stimulates [35S]GTPγS binding to RBL-2H3 cell membranes. MRS2690 enhances antigen (NP-BSA)-, C3a-induced β-hexosaminidase (β-Hex) release. MRS2690can be used for ischemic heart disease.
For research use only. We do not sell to patients.
- CAS No.: 7077-89-6
- Formula: C15H24N2O16P2S
- Molecular Weight:582.37
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| COS-7 | EC50 |
0.049 μM
Compound: 15, MRS-2690
|
Agonist activity at human P2Y14 expressed in COS7 cells assessed as stimulation of PLC-mediated [3H]inositol hydrolysis
Agonist activity at human P2Y14 expressed in COS7 cells assessed as stimulation of PLC-mediated [3H]inositol hydrolysis
|
[PMID: 17407275] |
| COS-7 | EC50 |
0.049 μM
Compound: 2
|
Agonist activity at human P2Y14 receptor expressed in human COS7 cells
Agonist activity at human P2Y14 receptor expressed in human COS7 cells
|
[PMID: 19502066] |
| COS-7 | EC50 |
11 μM
Compound: 4
|
Agonist activity at recombinant human P2Y14 receptor expressed in African green monkey COS7 cells co-transfected with Galphaqi assessed as stimulation of phospholipase Cbeta
Agonist activity at recombinant human P2Y14 receptor expressed in African green monkey COS7 cells co-transfected with Galphaqi assessed as stimulation of phospholipase Cbeta
|
[PMID: 25868749] |
In Vitro
MRS2690 (0.001-10 μM) elicits concentration-dependent contractions of porcine isolated coronary arteries at basal tone (log EC50 = 6.30 M)[1].
MRS2690 (0.001-10 μM) shows enhanced concentration-dependent contractile responses in porcine coronary arteries pre-treated with Forskolin (HY-15371) plus U46619 (HY-108566) (Rmax = 1.77 g),which can be blocked by the P2Y14 antagonist PPTN (HY-110322A), but not affected by the P2Y6 antagonist MRS2578 (HY-13104)[1].
MRS2690 (10 μM) significantly reduces forskolin-induced VASP phosphorylation (an indicator of cAMP levels) in porcine coronary arteries[1].
MRS2690 (0.0001-1000 nM) induces intracellular calcium mobilization in RBL-2H3 cells in a concentration-dependent manner with an EC50 of 538 nM[2].
MRS2690 (0.0001-100 nM) stimulates [35S]GTPγS binding to RBL-2H3 cell membranes in a concentration-dependent manner with an EC50 of 8.1 nM[2].
MRS2690 (1 μM) activates P38 mitogen-activated protein kinase (MAPK) in RBL-2H3 cells[2].
MRS2690 alone cannot induce β-hexosaminidase (HEX) release, but it concentration-dependently enhances antigen (DNP-BSA)-induced HEX release in RBL-2H3 cells primed with anti-DNP-BSA antibody, with an EC50 of 103 nM[2].
MRS2690 (1 μM, 50 min) significantly enhances antigen (NP-BSA)-, C3a-induced β-hexosaminidase (β-Hex) release in LAD2 cells[3].
MRS2690 (10-1000 nM) significantly induces platelet-dependent neutrophil chemotaxis towards Macrophage derived chemokine (MDC, CCL22) in a concentration-dependent manner[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 7077-89-6
-
Molecular Weight 582.37
-
Formula C15H24N2O16P2S
-
SMILES
OC[C@H]1O[C@@H]([C@@H]([C@H]([C@@H]1O)O)O)OP(O)(OP(O)(OC[C@@H]2[C@@H](O)[C@@H](O)[C@H](N3C(NC(C=C3)=O)=S)O2)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Calcium Spark Assay
Calcium sparks are localized, transient increases in intracellular calcium concentration ([Ca2+]i) that occur in cardiac myocytes and represent elementary events underlying excitation-contraction coupling. These events are generated by the coordinated opening of clusters of ryanodine receptors (RyRs) on the sarcoplasmic reticulum membrane, leading to a brief release of Ca2+ into the cytosol. The detection and analysis of calcium sparks provide insights into the mechanisms of calcium handling and signaling in cardiac cells. Imaging techniques using fluorescent calcium indicators such as Fluo-3 are employed to visualize these subcellular calcium transients with high spatial and temporal resolution. The protocol is based on established methodologies described in primary literature for both experimental measurement and automated analysis of calcium sparks.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Ca2+ Staining Technique
Ca2+ staining is an experimental technique that utilizes specific fluorescent probes (such as Fluo-4 AM, Fura-2, etc.) to qualitatively or quantitatively detect dynamic changes in intracellular Ca2+ concentrations; this is achieved by monitoring the changes in fluorescent signals generated when these probes bind to free intracellular calcium ions. The underlying principle relies primarily on the presence of chelating groups within the probe's molecular structure that possess high affinity for calcium ions.
Purity & Documentation
References
[1]. Abbas ZSB, et al. UDP-sugars activate P2Y14 receptors to mediate vasoconstriction of the porcine coronary artery. Vascul Pharmacol. 2018 Apr;103-105:36-46. [Content Brief]
[2]. Gao ZG, et al. UDP-glucose acting at P2Y14 receptors is a mediator of mast cell degranulation. Biochem Pharmacol. 2010 Mar 15;79(6):873-9. [Content Brief]
[3]. Gao ZG, et al. The role of P2Y(14) and other P2Y receptors in degranulation of human LAD2 mast cells. Purinergic Signal. 2013 Mar;9(1):31-40. [Content Brief]
[4]. Amison RT, et al. Lipopolysaccharide (LPS) induced pulmonary neutrophil recruitment and platelet activation is mediated via the P2Y1 and P2Y14 receptors in mice. Pulm Pharmacol Ther. 2017 Aug;45:62-68. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)